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Summary
Objective:  To  review  treatment  options  in  a  rare  type  of  parotid  tumor,  in  a  clinical  case  study.
Case study:  A  62-year-old  woman  presenting  with  recurrence  of  acinic  cell  carcinoma  of  the
parotid gland  with  invasion  of  the  skull  base  was  treated  by  external  3D  conformational  radi-
ation, having  refused  large-scale  exeresis.  Sixty-six  Gy  (70  Gy  equivalent)  were  delivered  in
2007. Clinical  and  paraclinical  follow-up  found  regular  tumor  volume  regression  over  a  2.5-year
period without  side-effects  of  radiation.
Discussion:  There  are  no  speciﬁc  data  on  the  efﬁcacy  of  external  radiation  therapy  in  acinic  cell
carcinoma;  reports  on  exclusive  radiation  treatment  of  salivary  gland  cancer  include  different
histological  types.  Exclusive  radiation  treatment  should  be  at  least  66—70  Gy,  preferably  by
neutron- or  hadrontherapy.
Conclusion:  Management  of  acinic  cell  carcinoma  of  the  parotid  is  surgical  with  possible  sec-
ondary radiation  therapy;  exclusive  external  radiation  therapy  is,  however,  an  option  in  case
of contra-indication  for  surgery  or  patient  refusal.
© 2011  Elsevier  Masson  SAS.  All  rights  reserved.
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aIntroduction
Salivary  gland  cancer  is  rare,  with  incidence  in  France  esti-
mated  at  0.3  to  0.5/100  000  in  1995  [1].  Curative  treatment
is  surgical,  possibly  completed  with  postoperative  radiation
in  case  of  poor  prognosis  factors  (micro-  or  macroscopi-
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doi:10.1016/j.anorl.2011.02.014ally  affected  exeresis  margins,  elevated  histologic  grade,
r  perineural  invasion  [2]).  Exclusive  external  radiation  ther-
py  (ERT)  is  an  option  where  surgery  is  unfeasible  (skull  base
xtension,  or  comorbidity)  or  refused  by  the  patient  [3].
he  one  prospective  study  of  this  situation  [4]  showed  high-
nergy  neutron  radiation  to  be  more  effective  than  X-rays
n  terms  of  locoregional  control  of  non-operable  tumor.
Acinic  cell  carcinoma  is  a  rare  (2.5%),  slow-growth
orm  of  salivary  gland  cancer  [5].  There  are  no  spe-
iﬁc  data  on  the  efﬁcacy  of  radiation  therapy  in  this
ndication.
served.
1 G.  Buiret  et  al.
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Figure  2  T1-weighted  MRI  without  contrast,  January  2007
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We  report  the  case  of  a  62  year-old  woman  presenting
ith  locally  advanced  recurrence  of  acinic  cell  carcinoma
f  the  left  parotid  gland  with  skull  base  invasion,  managed
y  lymph-node  curage  and  3D  conformational  ERT  (3DCRT).
ase study
 62-year-old  woman,  with  no  history  other  than  her  parotid
athology,  consulted  in  December  2006  for  locoregional
ecurrence  of  acinic  cell  carcinoma  of  the  left  parotid  gland.
n  1998,  she  had  undergone  total  left  parotidectomy  with
psilateral  curage.  Tumor  exeresis  was  complete,  without
apsule  rupture;  the  9-lymphadenectomy  nodes  were  free
f  tumor  cells.  In  2003,  the  patient  suffered  local  recur-
ence,  but  refused  surgical  revision.  In  December  2006,
he  showed  left  parotid  space  tumor  with  parapharyngeal
xtension  and  ﬁxed  10-cm  left  jugulo-carotid  adenopathy.
T  and  MRI  also  showed  invasion  of  the  inferior  side  of  the
emporal  bone,  with  conserved  inner  and  middle  ear  and
rain  structures  and  no  meningeal  involvement.  Thoracic
T  and  bone-scan  found  no  metastasis.  Parotid  cytopunc-
ure  demonstrated  recurrence  of  acinic  cell  tumor.  The
atient  again  refused  surgical  treatment  of  the  tumor  site,
earing  facial  palsy,  and  was  therefore  offered  radiation
herapy  preceded  by  lymphadenectomy.  Anatomopathologic
tudy  of  the  functional  curage  specimen  taken  in  March
007  (Fig.  1)  found  a  single  lymph  node  with  capsule  rup-
ure.  The  patient  failed  to  attend  her  April  radiation  session
nd,  in  June  2007,  underwent  revision  for  a  4  ×  3  cm  left
rea  II-A  lymph-node  recurrence.  The  parotid  space  tumor
ass  was  still  ﬁxed,  with  maximal  diameter  of  6  ×  6  cm.
 new  MRI  morphologic  assessment  found  3.5  cm-diameter
rea  II-A  and  2.5  cm-diameter  area  IV  adenopathies  with
.3  cm  progression  in  tumor  size  toward  the  skull  base,  still
especting  the  meninx  and  the  brain  (Fig.  2).  The  patient
till  refused  extensive  parotid  surgery,  but  agreed  again  to
ymphadenectomy  for  tumor  reduction,  performed  on  June
6,  2007  (two  adenopathies,  both  with  ruptured  capsules)
nd  followed  by  accelerated  hypofractionated  conforma-
ional  radiation  therapy.  Simulation  was  performed  for  X-ray
DCRT  and  intensity  modulation  radiation  therapy  (IMRT),
igure  1  Histology  of  the  node.  Round  or  polyhedral  cells,
ith cytoplasmic  basophilic  granulations.
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dbefore  radiation  therapy).  Arrow  shows  skull  base  involvement.
he  patient  having  refused  carbon  ion  hadrontherapy.  In  both
imulations,  more  than  95%  of  the  tumor  volume  received
ore  than  95%  of  the  prescribed  dose  of  70  Gy.  As  the  dose
elivered  to  at-risk  organs  (brain,  lens  and  ocular  globes,
nd  contralateral  parotid)  was  similar  in  both  cases,  6-ﬁeld
DCRT  was  performed.  Between  August  and  December  2007,
he  patient  received  a  total  of  66  Gy  (2.2  Gy  5  times  per
eek  over  30  sessions,  equivalent  to  70  Gy)  to  the  macro-
copic  tumor  volume,  and  50  Gy  (2  Gy/session)  to  the  left
ervico-subclavicular  lymph-node  chain.
Acute  toxicity  was  moderate,  with  grade-1  radiodermati-
is  and  grade-1  radiomucitis.
The  patient  was  followed  up  every  2  months  during  the
rst  year,  then  every  3  months  with  MRI  every  6  months
Fig.  3a  and  b).  No  locoregional  or  remote  recurrence  was
bserved;  indeed,  tumor  volume  diminished.  Quality  of  life
emained  very  good,  without  late  toxicity  due  to  the  ERT.
iscussion
he  originality  of  the  present  observation  lies  in  the  good
ocoregional  control  observed  at  2.5  years  in  this  case  of
arotid  recurrence  with  skull  base  invasion  following  3DCRT
t  a  dose  equivalent  to  70  Gy.
Acinic  cell  carcinoma  epidemiology  is  variable  according
o  the  literature.  The  reference  series  (the  largest)  would
eem  to  be  the  1353  cases  recorded  in  the  American  National
ancer  Database  between  1985  and  1995  [6].  Predominance
as  female  (58%),  with  a  median  age  of  52  years,  and  pre-
ominantly  parotid  location.  There  are,  however,  no  speciﬁc
ata  on  ERT  efﬁcacy  in  acinic  cell  carcinoma,  and  series  of
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RFigure  3  a:  T1-weighted  MRI  with  contrast,  June  2008  (follow
2009. Arrow  shows  reduced  skull  base  tumor  volume.
exclusive  radiation  therapy  for  salivary  gland  cancer  include
varying  histology.  Terhaard  et  al.  [7],  analyzing  498  salivary
gland  cancer  patients  managed  by  surgery,  surgery  associ-
ated  to  ERT  or  exclusive  ERT  (non-operable  patients  and
metastasis),  showed  that  exclusive  radiation  needed  to  be  at
least  66-70  Gy,  due  to  a  dose-response  threshold.  The  5-year
locoregional  control  rate  in  salivary  gland  cancer  patients
managed  by  exclusive  X-ray  and  electron  radiation  (non-
operable  patients,  refusal  of  surgery  [8]  or  incompletely
resectable  tumor  [9])  ranged  from  56  to  70%,  and  from  40
to  59%  at  10  years  [8,9]. Locoregional  control  rates  follow-
ing  surgery  and  postsurgical  ERT  ranged  from  88  to  91.4%
at  5  years  [6],  and  were  83  and  67%  at  10  and  20  years,
respectively  [10].
Treatment  efﬁcacy  results  and  prognostic  factors  mainly
derive  from  retrospective  univariate  analyses,  to  be
interpreted  with  caution  [7],  and  conclusions  drawn
from  subgroup  analyses  are  unsure.  Laramore  et  al.’s
[4]  prospective  study  of  exclusive  radiation  therapy  in
non-operable  patients,  for  example,  was  terminated  pre-
maturely  due  to  the  greater  locoregional  control  obtained
with  neutrons  as  compared  to  X-rays  (56%  vs.  17%  at
10  years),  at  the  cost  of  increased  rates  of  acute  (69%
vs.  33%)  and  severe  complications.  Given  the  small  num-
ber  of  patients  included  (13  for  neutrons  vs.  12  for
X-rays),  the  distribution  of  histological  types  was  non-
homogeneous  (squamous  cell  carcinoma:  33%  X-rays  vs.
8%  neutrons;  acinic  cell  carcinoma:  0%  X-rays  vs.  23%
neutrons),  although  they  affect  survivorship  and  recur-
rence.diation  therapy);  b:  T1-weighted  MRI  with  contrast,  November
onclusion
here  are  no  large  series  reported  for  acinic  cell  carcinoma.
ost  authors,  extrapolating  from  salivary  gland  cancer  data,
gree  on  a  curative  sequence  of  surgery  possibly  followed
y  ERT  in  case  of  negative  prognostic  factors.  Non-operable
atients  should  receive  radiation  therapy,  preferably  using
eutrons  or  carbon  ions,  at  a  dose  of  at  least  66  Gy.  The  lit-
rature,  however,  does  not  report  the  use  of  IMRT,  although
cinic  cell  carcinoma  patients  have  doubtless  received  such
reatment.  The  present  clinical  case  shows  the  feasibil-
ty  and  the  excellent  tolerance  of  exclusive  3DCRT  at  30
onths’  follow-up  in  this  patient.
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